Clinical Trial

Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ -- Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management,…

1 year ago

New ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General Neurologists

Groundbreaking thinkALS™ Tool Empowers Providers to Identify and Refer Patients Quicker ARLINGTON, Va., Dec. 10, 2024 /PRNewswire/ -- It can take…

1 year ago

Echo IQ Signs Integration Agreement With Flagship US Hospital

Integration agreement secured with Beth Israel Deaconess Medical Center, Boston USA Integration follows successful trial of EchoSolv-AS by Beth Israel…

1 year ago

Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress

WELLINGTON, FL and HIGHLANDS RANCH, CO / ACCESSWIRE / December 10, 2024 / Cellev8 Nutrition Inc. (OTC Pink:CELV) and Vivos…

1 year ago

Neuropathy Action Foundation Launches White Paper on the Promise and Potential Hazards of Artificial Intelligence (AI) for Neuropathy

NAF calls for increased awareness and advocacy around use of AI to prevent potential abuses SANTA ANA, Calif., Dec. 10,…

1 year ago

Lindus Health Releases “All-in-One Cardiovascular CRO” Offering for Clinical Trials Serving Cardiovascular Health

NEW YORK, Dec. 10, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science…

1 year ago

DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder

MMJ Submits FDA Investigational New Drug Application for Cannabis-Derived Drug WASHINGTON, DC / ACCESSWIRE / December 10, 2024 / MMJ…

1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne --…

1 year ago

MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE /…

1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce…

1 year ago